This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TLR4 / Toll-like receptor 4 · IHC design guide
Design Immunohistochemistry for TLR4
Plan chromogenic TLR4 IHC with bone marrow as a high-staining control and the catalog antibody at 0.5–1 μg/ml (HPA tissue IHC; datasheet). Assess cytoplasmic staining in immune-cell subsets while allowing for TLR4 at the membrane and in endosomes (HPA tissue IHC; UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TLR4 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Immune-cell cytoplasm (HPA tissue IHC); membrane and early endosome (UniProt) | |
| Staining pattern | Selective cytoplasmic staining in immune-cell subsets (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Bone marrow+2 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | LPS can shift TLR4 from membrane to endosomes (UniProt) | |
| Regulation | LPS can change TLR4 distribution (UniProt) | |
| Isoform / epitope | 3 isoforms; check whether the epitope is extracellular or cytoplasmic (UniProt) |
Section 1
Recommended TLR4 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet) with four published TLR4 IHC protocols (PMC3546871; PMC13603005; PMC10319487; PMC8026365).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet PA1484); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-TLR4, 0.5-1μg/ml (datasheet PA1484) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TLR4-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: High). HPA tissue profile: Selective cytoplasmic expression in subsets of immune cells. No signal in the no-primary control. |
💡Decision noteStart with citrate HIER at pH 6.0, 95–98 °C for 20 min (page retrieval); the cyst study used EDTA-based retrieval (PMC13603005).
Section 2
What Is the Expected TLR4 Staining Pattern?
TLR4 is a single-pass membrane receptor with an extracellular region and a cytoplasmic tail (UniProt O00206 topology). In tissue IHC, expect selective cytoplasmic staining in subsets of immune cells, especially hematopoietic cells in bone marrow and cells in splenic red pulp (HPA tissue IHC). HPA rates the tissue pattern Approved, with external verification pending (HPA tissue IHC).
| Distinct staining in bone marrow hematopoietic cells, with a subset of cells more prominent than surrounding tissue (HPA: High in hematopoietic cells). | This is a useful positive pattern for paraffin IHC. Judge the stained cells and their distribution together: HPA describes selective cytoplasmic expression in immune-cell subsets, so uniform staining throughout the section would need scrutiny (HPA tissue IHC). |
| Moderate staining in splenic red pulp cells or lymph-node non-germinal center cells (HPA: Medium in both populations). | These patterns fit the reported tissue distribution. A lower apparent intensity than bone marrow can still be compatible with the reference observations; compare the relevant cell populations, not whole-section color alone (HPA tissue IHC; general IHC practice). |
| Predominantly nuclear staining, without a convincing signal in expected immune-cell populations. | Nuclear staining does not match the reported membrane, endosomal or ruffle locations, or HPA's selective cytoplasmic tissue pattern (UniProt O00206 subcellular location; HPA tissue IHC). Treat it as suspect and check antibody specificity and detection controls (general IHC practice). |
| Strong signal in adipocytes or bronchial respiratory epithelial cells, with little staining in expected positive cells. | HPA reports TLR4 as not detected in those particular cell types (HPA tissue IHC). Check for cross-reactivity or endogenous detection activity before interpreting the signal as TLR4; those HPA observations do not establish that every cell in either tissue is negative (general IHC practice). |
| Diffuse color across cells, extracellular spaces and the blank slide area. | A poorly localized signal is hard to reconcile with selective cellular staining (HPA tissue IHC). Compare a no-primary control, reagent background and tissue morphology; background alone cannot identify which step caused the problem (general IHC practice). |
💡Expected TLR4 appearanceA credible positive is selective, appreciable staining in bone marrow hematopoietic cells, with compatible staining in splenic red pulp or lymph-node non-germinal center cells; diffuse or predominantly nuclear color is suspect (HPA tissue IHC; UniProt O00206 subcellular location).
| Cell compartment and stimulus | TLR4 is reported at the cell membrane, early endosome and ruffles; LPS stimulation can move membrane-associated TLR4 toward endosomes (UniProt O00206 subcellular location). HPA's tissue IHC profile is selectively cytoplasmic, so cytoplasmic color alone is not a reason to reject a slide (HPA tissue IHC). |
| Choice of reference cells | HPA reports High staining in bone marrow hematopoietic cells and Medium staining in splenic red pulp and lymph-node non-germinal center cells (HPA tissue IHC). Its negative entries identify specific cell populations, such as adipocytes, rather than entire organs (HPA tissue IHC). |
| Antibody evidence | HPA lists HPA049174 and CAB004025 as Approved for IHC; its tissue reliability is also Approved but pending external verification (HPA antibodies; HPA tissue IHC). This supports use of the reported pattern as a reference while leaving individual experimental specificity to be checked (general IHC practice). |
| Antigen structure | The mature TLR4 chain is residues 24–839 after removal of its 1–23 signal peptide; residues 24–631 are extracellular and 653–839 cytoplasmic (UniProt O00206 processing and topology). The record does not locate either antibody's epitope, so compartment or retrieval requirements cannot be assigned from topology alone. |
| Detection chemistry | Chromogenic IHC can show reagent or endogenous activity unrelated to primary-antibody binding (general IHC practice). A no-primary control helps distinguish that activity from a specific cell-associated pattern; HPA staining levels do not establish the source of background on a new slide (HPA tissue IHC; general IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| No staining in bone marrow hematopoietic cells (HPA: High). | The positive reference has failed, but the supplied sources do not identify a TLR4-specific fixation or retrieval failure. | Confirm tissue identity, antibody use and detection-control performance; review the catalog antibody's IHC-P instructions before changing retrieval or dilution (general IHC practice). |
| Weak staining in spleen or lymph node (HPA: Medium). | Those populations have a lower reported level than bone marrow hematopoietic cells (HPA tissue IHC); weak color alone does not prove assay failure. | Score the specified red pulp or non-germinal center cells and compare a bone marrow positive control processed in the same run (HPA tissue IHC; general IHC practice). |
| Widespread nuclear staining. | A nuclear-dominant pattern conflicts with the supplied localization record (UniProt O00206 subcellular location; HPA tissue IHC). | Check no-primary and antibody-specificity controls, then reassess the stained cells against the expected tissue distribution (general IHC practice; HPA tissue IHC). |
| Adipocytes or bronchial respiratory epithelial cells stain strongly (HPA: Not detected). | Cross-reactivity or endogenous detection activity is possible; HPA's negative calls apply to those named cell types (HPA tissue IHC; general IHC practice). | Inspect a no-primary control and a known-positive cell population in the same run before assigning the unexpected color to TLR4 (general IHC practice; HPA tissue IHC). |
| Diffuse brown background obscures individual cells. | Non-specific reagent signal or endogenous detection activity can obscure a selective pattern (general IHC practice; HPA tissue IHC). | Use a no-primary control to localize the background, then review blocking, washing and detection steps under the chosen IHC-P workflow (general IHC practice). |
| IF/ICC shows plasma-membrane or Golgi signal: is that expected? | HPA supports plasma-membrane localization in ICC-IF but calls its Golgi assignment uncertain; HPA049174 has Uncertain ICC validation (HPA subcellular; HPA antibodies). | Interpret the membrane signal with suitable IF controls and treat Golgi staining cautiously; use the separate IF/ICC guide for that application (HPA subcellular; general IF practice). |
Experiment evidence
IHC & IF images showing TLR4 staining
PA1484 · IHCAnti-TLR4 antibody, PA1484, IHC(P) IHC(P): Human Lung Cancer Tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000136869-TLR4/tissue/cerebral+cortex#imid_17396231
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000136869-TLR4/tissue/colon#imid_17396173
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000136869-TLR4/tissue/liver#imid_17396158
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000136869-TLR4/tissue/kidney#imid_17396159
HPA · ICC-IF RT-4Human Protein Atlas immunofluorescence, RT-4, antibody HPA049174; green = TLR4, blue = nucleus, red = microtubules.
HPA · ICC-IF RT-4Human Protein Atlas immunofluorescence, RT-4, antibody HPA049174; green = TLR4, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TLR4 IHC & IF
🧪Run bone marrow first and assess staining in hematopoietic cells, the reported High population (HPA: bone marrow hematopoietic cells, High). Use adipose tissue adipocytes as the negative tissue (HPA: adipocytes, Not detected); on the marrow slide, internal negative cells should lack specific TLR4 staining, but no marrow cell population is established as negative by the supplied HPA rows (HPA: bone marrow hematopoietic cells, High).
Positive control tissue: Bone marrow (Hematopoietic cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show TLR4 in RT-4, U-251MG, U2OS, with annotated localisation: Golgi apparatus (uncertain), Plasma membrane (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality; use TLR4 knockout material as a biological negative, or peptide blocking if the antibody’s immunizing peptide is available (standard IHC practice). In bone marrow, block endogenous peroxidase for chromogenic detection and check autofluorescence if using IF (standard IHC/IF practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected PA1484 tissue-IHC caption does not state a fixative (PA1484 caption: fixative not stated). Retrieval dependence is unreported, so compare retrieved and unretrieved paraffin sections during optimization (standard IHC practice). The supplied evidence does not establish whether frozen sections or IF are easier for TLR4; in bone marrow, endogenous peroxidase can complicate chromogenic interpretation (standard IHC practice).
HPA tissue IHC evidence for TLR4
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Lymph node | Non-germinal center cells | Medium | Protein (IHC) | HPA → |
| Spleen | Cells in red pulp | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced TLR4 IHC Tips
Troubleshoot TLR4 staining in paraffin sections by checking retrieval, cell identity, subcellular pattern and controls before assigning biological meaning.
What retrieval should I use when TLR4 staining is weak in paraffin sections?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 minutes (page retrieval setting). Let slides cool in buffer, then compare staining with a positive control processed in the same run; consistent cooling and matched handling make the comparison interpretable (standard IHC practice). If signal remains weak, test a second retrieval condition on adjacent sections as a fallback, changing one variable at a time and recording any increase in background (standard IHC practice). Assess membrane and cytoplasmic staining in immune cell subsets, since TLR4 occurs at the cell membrane and in early endosomes, while tissue IHC shows selective cytoplasmic expression (UniProt O00206 localisation; HPA tissue IHC profile).
How should I troubleshoot inconsistent TLR4 staining between similarly processed sections?
The selected PA1484 tissue-IHC caption does not state a fixative, so target-specific fixation sensitivity is unknown (PA1484 tissue-IHC caption). Record the actual fixative, fixation duration, processing schedule and section age for each case before comparing intensity; these variables can affect antigen preservation in routine IHC (standard IHC practice). Process adjacent sections together and apply the same citrate pH 6.0 retrieval for 20 minutes to isolate handling differences (page retrieval setting; standard IHC practice). Include a same-run positive tissue control and compare cell-specific patterns, rather than assigning a fixation effect from staining differences alone (standard IHC practice).
Should TLR4 appear at the membrane, in the cytoplasm, or both?
Expect a membrane-associated pattern where TLR4 is accessible at the cell surface, with possible intracellular staining because the receptor also localises to early endosomes (UniProt O00206 localisation). Tissue IHC reports selective cytoplasmic expression in subsets of immune cells, whereas subcellular imaging supports plasma membrane localisation and labels Golgi localisation uncertain (HPA tissue IHC profile; HPA subcellular). Examine matched sections at 20× and 40× to distinguish a cell rim from granular cytoplasm and to identify the stained cell population (standard IHC practice). Interpret a changed membrane-to-cytoplasmic balance in light of stimulation and cell context, since TLR4 can undergo ligand-associated internalisation (UniProt O00206 function and localisation).
How can epitope position change the TLR4 pattern I see?
TLR4 has 3 reported isoforms, so check the catalog antibody’s stated immunogen against the isoform sequence before treating absent staining as absent protein (UniProt O00206 isoforms; standard IHC practice). The canonical receptor has an extracellular region at residues 24–631, a transmembrane segment at 632–652 and a cytoplasmic region at 653–839 (UniProt O00206 topology). Its extracellular region carries 10 listed glycosylation sites, which makes epitope identity relevant when comparing antibodies or interpreting accessibility (UniProt O00206 glycosylation; standard IHC practice). For an unresolved or undisclosed epitope, compare independently mapped antibodies and an appropriate positive control under the same retrieval condition before assigning an isoform-specific result (standard IHC practice).
How should I check a TLR4 IHC pattern with multiplex IF?
On a separate IF/ICC guide workflow, pair TLR4 with a validated marker for the immune cell population being examined; tissue IHC places TLR4 in subsets of immune cells (HPA tissue IHC profile; standard IF practice). Choose fluorophores after inspecting unstained tissue in each channel, and place a dim target signal in a channel with lower tissue autofluorescence (standard IF practice). Match permeabilisation to the antibody’s mapped epitope: a cytoplasmic epitope needs access across the membrane, while an extracellular epitope may be assessed without that step (UniProt O00206 topology; standard IF practice). Record the epitope and acquisition settings alongside the result, because IF compartment calls should be compared with IHC only at the level supported by each method’s controls (standard IF and IHC practice).
What should I check when TLR4 chromogen covers most of the section?
Check the no-primary control and a known lower-staining cell population before raising the threshold for a positive call (standard IHC practice; HPA tissue IHC). Block endogenous peroxidase before chromogenic detection, then inspect whether residual colour follows cells or tissue structures independently of the primary antibody (standard chromogenic IHC practice). Titrate the primary antibody and detection exposure on adjacent sections, keeping citrate pH 6.0 retrieval for 20 minutes constant during the comparison (page retrieval setting; standard IHC practice). Treat widespread staining cautiously when it conflicts with selective immune-cell expression in tissue IHC, and check section edges and damaged areas for uneven reagent accumulation (HPA tissue IHC profile; standard IHC practice).
How should I quantify TLR4 across sections with different immune-cell content? ⚠ ANSWER MARKED FOR VERIFICATION
Define the compartment and cell population before scoring, because TLR4 can be membrane-associated or intracellular and tissue IHC highlights immune-cell subsets (UniProt O00206 localisation; HPA tissue IHC profile). Report an H-score from intensity and percentage positive cells, or report positive-cell density per mm² within a prespecified region (standard IHC quantification practice). Normalise counts to the number of eligible cells or analysed tissue area, and record immune-cell abundance so differences in cellular composition remain visible (standard IHC quantification practice). Apply one staining threshold to matched batches and review no-primary controls and section quality before comparing scores across cases (standard IHC practice).
When is a TLR4-positive IHC result credible rather than artefactual?
A credible call should identify stained cells and a plausible membrane or intracellular pattern, with selective cytoplasmic staining in immune-cell subsets supported by tissue IHC (UniProt O00206 localisation; HPA tissue IHC profile). Compare a same-run positive control and a no-primary control, then inspect the finding at 20× and 40× for cellular boundaries (standard IHC practice). Discount staining confined to cut edges, necrotic areas or sites of residual endogenous enzyme activity when those patterns also appear in controls (standard chromogenic IHC practice). In mixed tissues, do not assign signal to tumour or epithelial cells merely because adjacent immune cells stain; identify the positive cell type directly (HPA tissue IHC profile; standard IHC interpretation practice).
Boster reagents
Best TLR4 / Toll-like receptor 4 IHC Antibodies
PA1484 is a human-reactive anti-TLR4 antibody tested for IHC (catalog: PA1484 applications and reactivity), with an IHC paraffin-section image of human lung cancer tissue (PA1484 image caption).
Real IHC data
Anti-Toll-like receptor 4 TLR4 Antibody ®
Cat # PA1484
PA1484 is the only SKU listed, and its applications include IHC (catalog: PA1484 applications). Its own image documents IHC on human lung cancer paraffin sections (PA1484 image caption).
Which to pick: For human tissue IHC, choose PA1484: its image shows paraffin-section staining (PA1484 image caption), and the listed IHC dilution is 0.5–1 μg/ml (PA1484 datasheet). No listed SKU is validated for IF/ICC or other species (catalog: PA1484 applications and reactivity). The image caption does not report the fixative (PA1484 image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O00206 (TLR4_HUMAN, Toll-like receptor 4).
- Human Protein Atlas. TLR4 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. TLR4 subcellular location (ICC-IF): Localized to the plasma membrane and the Golgi apparatus..
- Human Protein Atlas. TLR4 antibody validation summary (2 antibodies).
- The association of down-regulated toll-like receptor 4 expression with airflow limitation and emphysema in smokers. Respiratory research 2012 — PMC3546871.
- TLR4 expression and its immunopathogenic role in inflammatory radicular cysts: a clinicopathological study. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2026 — PMC13603005.
- Immunostaining patterns reveal potential morphogenetic role of Toll-like receptors 4 and 7 in the development of mouse respiratory system, liver and pancreas. Anatomy & cell biology 2023 — PMC10319487.
- Impaired Colonic Contractility and Intestinal Permeability in Symptomatic Uncomplicated Diverticular Disease. Journal of neurogastroenterology and motility 2021 — PMC8026365.
- PubMed PMID:9237759 — UniProt-cited evidence.
- PubMed PMID:9435236 — UniProt-cited evidence.
- PubMed PMID:11104518 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TLR4 (Toll-like receptor 4). Expected localisation Immune-cell cytoplasm (HPA tissue IHC); membrane and early endosome (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: PA1484 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bone marrow (Hematopoietic cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet PA1484); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-TLR4, 0.5-1μg/ml (datasheet PA1484); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: LPS can shift TLR4 from membrane to endosomes (UniProt); Isoform / epitope: 3 isoforms; check whether the epitope is extracellular or cytoplasmic (UniProt); Regulation: LPS can change TLR4 distribution (UniProt). Evidence: UniProt O00206, HPA tissue IHC · Approved, HPA ICC-IF · plasma membrane and the Golgi apparatus., Datasheet PA1484, PMC3546871, PMC13603005. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TLR4/immunohistochemistry-ihc-guide.